Amsacrine cardiotoxicity: assessment of ventricular function by radionuclide angiography.
Serial assessment of ventricular function by means of a nuclear medicine technique was performed in six patients with malignant disease receiving chemotherapy with amsacrine. Two patients who received treatment long enough so that greater than 580 mg/m2 of the drug was administered showed a significant decrease in left ventricular ejection fraction. Four patients who received total doses of 325-510 mg/m2 of amsacrine did not experience significant change in their cardiac function.
D000368:Aged; D000609:Aminoacridines / Q000009:adverse effects*; D000677:Amsacrine; D000792:Angiography / Q000379:methods; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D006331:Heart Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging; D006352:Heart Ventricles / Q000000981:diagnostic imaging*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010997:Pleural Neoplasms / Q000188:drug therapy; D011877:Radionuclide Imaging; D013318:Stroke Volume; D016276:Ventricular Function
D000609:Aminoacridines; D000970:Antineoplastic Agents; D000677:Amsacrine